cefaclor sun cefaclor 250mg/5ml (as monohydrate) powder for oral liquid bottle
sun pharma anz pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; colloidal anhydrous silica; xanthan gum; sucrose; sodium benzoate; allura red ac; sodium citrate dihydrate; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.
cefaclor sun cefaclor 125mg/5ml (as monohydrate) powder for oral liquid bottle
sun pharma anz pty ltd - cefaclor monohydrate, quantity: 26.23 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; xanthan gum; sucrose; sodium citrate dihydrate; colloidal anhydrous silica; sodium benzoate; allura red ac; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.
ranbaxy-cefaclor
douglas pharmaceuticals limited - cefaclor monohydrate 535mg equivalent to cefaclor 500 mg (plus 2% overage.) - capsule - 500 mg - active: cefaclor monohydrate 535mg equivalent to cefaclor 500 mg (plus 2% overage.) excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin iron oxide black magnesium stearate methyl hydroxybenzoate ponceau 4r pregelatinised maize starch propyl hydroxybenzoate titanium dioxide
cefaclor capsule
alvogen, inc. - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg
cefaclor for suspension
avadel pharmaceuticals (usa), inc. - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 125 mg in 5 ml
cefaclor for suspension
aytu therapeutics, llc - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae, staphylococci, and streptococcus pyogenes note: β -lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes note: β -lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococ
cefaclor suspension
azorian pharma, llc - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae , staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae , and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis , caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclo
cefaclor (as monohydrate) 125mg / 5ml powder for suspension
drugmaker's labs inc - cefaclor (as monohydrate) - powder for suspension - 125mg / 5ml
cefaclor capsule
bryant ranch prepack - cefaclor (unii: 69k7k19h4l) (cefaclor - unii:69k7k19h4l) - cefaclor 250 mg
cefaclor capsule
bryant ranch prepack - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor anhydrous 250 mg